Selected article for: "kg day and kg mg day"
Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018
  • Document date: 2018_10_25
    • ID: 60ceejq1_262
    Snippet: Austin Kerns 1 , Nina Kieves 1 , Laurie Cook 2 , Sarah Moore 1 1 Ohio State University, Columbus, OH, USA, 2 Ohio State University, columbus, OH, USA Electronic von Frey anesthesiometry (VFA) has been previously reported by our laboratory and others as a useful method of mechanical quantitative sensory testing (QST) for evaluating neuropathic pain in dogs. Intraobserver agreement has been previously shown to be good to excellent; however, interob.....
    Document: Austin Kerns 1 , Nina Kieves 1 , Laurie Cook 2 , Sarah Moore 1 1 Ohio State University, Columbus, OH, USA, 2 Ohio State University, columbus, OH, USA Electronic von Frey anesthesiometry (VFA) has been previously reported by our laboratory and others as a useful method of mechanical quantitative sensory testing (QST) for evaluating neuropathic pain in dogs. Intraobserver agreement has been previously shown to be good to excellent; however, interobserver agreement has not been previously reported and is vital to the use of this technique in multicenter veterinary clinical trials in neuropathic pain. The goal of this study was to evaluate the interobserver agreement of sensory thresholds obtained using electronic VFA in a group of normal small breed dogs. No statistical difference between MTR and FA was noted between groups. AD and MD were significantly lower in dogs that did not recover. Findings support that quantitative imaging surrogates of axonal integrity may be important prognostic indicators in dogs with SCI. Despite studies demonstrating that lower doses of toceranib (2.4 -2.9 mg/kg every other day) provides drug exposure sufficient for target inhibition while reducing the frequency of drug-related adverse events, gastrointestinal (GI) toxicity continues to be the most commonly encountered side effect in dogs receiving toceranib at this dose. The degree of toxicity is variable among individual dogs and currently there are no clinical or molecular markers to identify those dogs that would benefit from the use of concomitant medications to prevent GI toxicities. This is critical as the development of GI toxicity significantly impacts patient morbidity and quality of life, decreases treatment intensity, increases the cost of treatment, and leads to discontinuation of therapy. The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 2 Anicom Specialty Medical Institute Inc., Shinjuku-ku, Tokyo, Japan, 3 The University of Tokyo, Tokyo, Tokyo, Japan

    Search related documents:
    Co phrase search for related documents
    • adverse event and concomitant medication: 1, 2, 3, 4
    • adverse event and drug exposure: 1, 2, 3
    • clinical trial and concomitant medication: 1, 2, 3, 4
    • clinical trial and drug exposure: 1, 2, 3, 4, 5, 6, 7